EP 0200322 B1 19900228 - HETEROCYCLIC COMPOUNDS
Title (en)
HETEROCYCLIC COMPOUNDS
Publication
Application
Priority
- CA 616585 A 19930311
- GB 8509164 A 19850410
Abstract (en)
[origin: EP0200322A1] Indole derivatives of the general formula: <CHEM> wherein R is phenyl, optionally substituted with halogen, lower alkyl or trifluroomethyl, or a hetero aromatic group, such as 2-thienyl, 3-thienyl, 2-furoyl 3-furoyl, 2-thiazol, 2-oxazol, 2-imidazole, 2-pyridyl, 3-pyridyl or 4-pyridyl; R<1> is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, lower alkylthio, trifluoromethyl, lower alkylsulfonyl, amino, lower alkylamino or lower di-alkylamino; "A" is nitrogen or carbon, and the dotted line indicates - when A is carbon - an optional bond; R<2> is hydrogen, cycloalkyl, lower alkyl or lower alkenyl, optionally substituted with one or two hydroxy groups, any hydroxy group present being optionally esterified with an aliphatic carboxylic acid radical having from two to twenty-four carbon atoms inclusive, or R<2> is the group <CHEM> wherein "n" is an integer of 2-6; X is oxygen or sulfur, or >C = X may constitute the group \CH = when Y is = N- or =CH-; Y is oxygen, sulfur, CH2 OR N R<3>, where R<3> is hydrogen or lower alkyl, lower alkenyl or a cycloalkylmethyl group, said "cycloalkyl" having from three to six carbon atoms inclusive; Z is -(CH2)m -, "m" being 2 or 3, or Z is -CH=CH- or 1,2-phenylene optionally substituted with halogen or trifluoromethyl, or Z is -CO(or S)CH2-; U is nitrogen or carbon, provided that when R<1> is chloro, A is nitrogen and R<2> is methyl or cyclohexyl, R may not be phenyl; as well as their pharmaceutically acceptable acid addition salts, are described as having pronounced activity in the treatment of psychoses. <??>Moreover, methods for the preparation of the indole derivatives of Formula 1 are described.
IPC 1-7
IPC 8 full level
C07D 409/14 (2006.01); A61K 31/395 (2006.01); A61K 31/40 (2006.01); A61K 31/403 (2006.01); A61K 31/404 (2006.01); A61K 31/44 (2006.01); A61K 31/4427 (2006.01); A61K 31/4433 (2006.01); A61K 31/445 (2006.01); A61K 31/495 (2006.01); A61P 9/00 (2006.01); A61P 25/00 (2006.01); A61P 25/18 (2006.01); A61P 43/00 (2006.01); C07D 209/14 (2006.01); C07D 209/40 (2006.01); C07D 333/00 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/04 (2006.01); C07D 405/14 (2006.01); C07D 409/04 (2006.01); C07D 413/14 (2006.01); C07D 417/04 (2006.01); C07D 417/14 (2006.01); C07D 471/00 (2006.01); C07D 487/00 (2006.01)
IPC 8 main group level
CPC (source: EP US)
A61P 9/00 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/18 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 209/40 (2013.01 - EP US); C07D 401/04 (2013.01 - EP US); C07D 401/14 (2013.01 - EP US); C07D 413/14 (2013.01 - EP US)
Citation (examination)
GB 1570374 A 19800702 - SAUBA LAB
Designated contracting state (EPC)
AT BE CH DE FR GB IT LI LU NL SE
DOCDB simple family (publication)
EP 0200322 A1 19861105; EP 0200322 B1 19900228; AU 5590186 A 19861016; AU 583607 B2 19890504; CA 1256437 A 19890627; CA 1338327 B 19960514; DK 157686 A 19861011; DK 157686 D0 19860408; DK 169674 B1 19950109; FI 861505 A0 19860409; FI 861505 A 19861011; FI 90976 B 19940114; FI 90976 C 19940425; HK 116793 A 19931105; IE 58370 B1 19930908; IE 860618 L 19861010; JP H064587 B2 19940119; JP S61236764 A 19861022; LU 90218 I2 19980427; NL 970016 I1 19970602; NL 970016 I2 19970901; US 4710500 A 19871201; US RE34299 E 19930629
DOCDB simple family (application)
EP 86301989 A 19860318; AU 5590186 A 19860409; CA 505930 A 19860404; CA 616585 A 19930311; DK 157686 A 19860408; DK 157686 D 19860408; FI 861505 A 19860409; HK 116793 A 19931028; IE 61886 A 19860310; JP 8029386 A 19860409; LU 90218 C 19980225; NL 970016 C 19970326; US 75951791 A 19910913; US 84691286 A 19860401